To be or not to be! Transvenous ICD's vs. Extravascular ICD's

Description

This is a debate involving a provocative area in emerging technologies for SCA prevention spanning many patient populations.

Learning Objectives

Review the current data examining the risks and benefits of Transnsvenous compared with Extravascular devices.
Describe the opportunities for ATP/bradycardia pacing in extravascular devices.
Summarize which patient populations may be better served with extravascular devices.

Session Chair(s)

Mark Schoenfeld, MD
Reinoud Knops, MD, PhD

Presentation

Extravascular ICDs are the Present and Future and Transvenous ICDs are Dinosaurs of the Past
Presenter(s): Pamela K. Mason, MD

Transvenous ICDs are the Gold Standard, Extravascular Devices are Just Gimmicks
Presenter(s): Lucas V. Boersma, MD, PhD

Rebuttal
Presenter(s): Pamela K. Mason, MD

Rebuttal
Presenter(s): Lucas V. Boersma, MD, PhD

Disclosures

Pamela Mason:

Boston Scientific (Honoraria/Speaking/Consulting Fee - Consulting)
Apple Inc. (Stocks – Publicly Traded - Ownership)
Medtronic,Inc. (Honoraria/Speaking/Consulting Fee - Consulting)
Philips (Honoraria/Speaking/Consulting Fee - Consulting)

Lucas Boersma:

Boston Scientific (Honoraria/Speaking/Consulting Fee - Consulting)
Medtronic (Honoraria/Speaking/Consulting Fee - Consulting)

Pamela Mason:

Boston Scientific (Honoraria/Speaking/Consulting Fee - Consulting)
Apple Inc. (Stocks – Publicly Traded - Ownership)
Medtronic,Inc. (Honoraria/Speaking/Consulting Fee - Consulting)
Philips (Honoraria/Speaking/Consulting Fee - Consulting)

Lucas Boersma:

Boston Scientific (Honoraria/Speaking/Consulting Fee - Consulting)
Medtronic (Honoraria/Speaking/Consulting Fee - Consulting)

To view all Heart Rhythm 2025 Faculty Disclosures, please click here.

Education Framework

Ventricular Tachyarrhythmias
-- Implantable Cardioverter-defibrillators (ICDs)
-- 227. Know how to select the appropriate ICD type and leads for a patient for transvenous, epicardial and subcutaneous technologies, including special populations such as the young, and those with congenital heart conditions, hemodialysis, and limited vascular access.

Summary


Availability:	No future session


Cost:	FREE


Credit Offered:	No Credit Offered

Recommended

Abstract Catalog 2025: ePosters

FREE